Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. TLSI
stocks logo

TLSI

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
13.02M
+57.63%
-0.112
-72%
15.12M
+64.91%
-0.080
-79.49%
16.86M
+50.32%
-0.044
-83.7%
Estimates Revision
The market is revising Downward the revenue expectations for TriSalus Life Sciences, Inc. (TLSI) for FY2025, with the revenue forecasts being adjusted by -0.29% over the past three months. During the same period, the stock price has changed by 34.27%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.29%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+104.29%
In Past 3 Month
Stock Price
Go Up
up Image
+34.27%
In Past 3 Month
Wall Street analysts forecast TLSI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TLSI is 11.60 USD with a low forecast of 10.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast TLSI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TLSI is 11.60 USD with a low forecast of 10.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.700
sliders
Low
10.00
Averages
11.60
High
16.00
Current: 6.700
sliders
Low
10.00
Averages
11.60
High
16.00
Canaccord Genuity
William Plovanic
Strong Buy
Maintains
$11
2025-03-28
Reason
Canaccord Genuity
William Plovanic
Price Target
$11
2025-03-28
Maintains
Strong Buy
Reason
Roth MKM
Jason Wittes
Strong Buy
Reiterates
$11
2025-01-24
Reason
Roth MKM
Jason Wittes
Price Target
$11
2025-01-24
Reiterates
Strong Buy
Reason
Cantor Fitzgerald
Prakhar Agrawal
Buy
Initiates
$10
2024-12-17
Reason
Cantor Fitzgerald
Prakhar Agrawal
Price Target
$10
2024-12-17
Initiates
Buy
Reason
Cantor Fitzgerald initiated coverage of TriSalus Life Sciences with an Overweight rating and $10 price target.
See All Ratings

Valuation Metrics

The current forward P/E ratio for TriSalus Life Sciences Inc (TLSI.O) is -25.82, compared to its 5-year average forward P/E of -4.08. For a more detailed relative valuation and DCF analysis to assess TriSalus Life Sciences Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.08
Current PE
-25.82
Overvalued PE
0.77
Undervalued PE
-8.93

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-8.65
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
9.18
Undervalued EV/EBITDA
-26.48

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
3.15
Current PS
0.00
Overvalued PS
6.48
Undervalued PS
-0.17
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

TLSI News & Events

Events Timeline

(ET)
2025-11-13
16:04:21
TriSalus Life Sciences Announces Q3 EPS of 96 Cents Compared to a Loss of 12 Cents Last Year
select
2025-08-12 (ET)
2025-08-12
16:03:36
TriSalus Life Sciences reports Q2 EPS (27c), consensus (22c)
select
2025-08-11 (ET)
2025-08-11
08:24:23
TriSalus publishes Pressure-Enabled Drug Delivery technology results
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
08-11Newsfilter
TriSalus Life Sciences Announces Publication of Safety and Efficacy Results for a Novel Pressure-Enabled Thyroid Embolization Technique

  • New Treatment Evaluation: TriSalus Life Sciences has published clinical data on its Pressure-Enabled Drug Delivery (PEDD) technology for thyroid parenchymal embolization, showing it as a safe and effective option for patients with symptomatic thyroid disease, achieving 100% technical and clinical success in a study of 22 patients.

  • Future Research Initiatives: A multi-institutional registry study called PROTECT is underway to further validate these findings and explore the broader applicability of pressure-enabled embolization techniques in treating benign thyroid conditions.

[object Object]
Preview
8.5
07-25Newsfilter
TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock

  • TriSalus Life Sciences Exchange Offer: TriSalus Life Sciences has completed its exchange offer for Preferred Stock, allowing shareholders to convert their shares into common stock at a rate of 3.3 shares per preferred share, with approximately 98.82% of outstanding preferred shares tendered.

  • Amendment Approval and Future Plans: Due to sufficient shareholder agreement, the company will amend the terms of the Preferred Stock, resulting in remaining shares converting to common stock at a slightly lower rate, while continuing to focus on innovative drug delivery technologies for cancer treatment.

[object Object]
Preview
8.5
06-24Newsfilter
TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock to Streamline Capital Structure

  • Exchange Offer Announcement: TriSalus Life Sciences has initiated an exchange offer for its Series A Convertible Preferred Stock, allowing shareholders to convert their preferred shares into common stock to simplify the company's capital structure and enhance transparency.

  • Consent Solicitation Details: The company is also seeking approval from preferred shareholders for an amendment that would enable automatic conversion of remaining preferred shares into common stock at a reduced exchange ratio, with a deadline for participation set for July 23, 2025.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is TriSalus Life Sciences Inc (TLSI) stock price today?

The current price of TLSI is 6.7 USD — it has increased 4.2 % in the last trading day.

arrow icon

What is TriSalus Life Sciences Inc (TLSI)'s business?

TriSalus Life Sciences, Inc. is an oncology-focused medical technology company. The Company is seeking to transform outcomes for patients with solid tumors by integrating its delivery technology with standard-of-care therapies, and with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and technology applications. The Company’s platform includes devices that utilize a proprietary drug delivery technology and a clinical-stage investigational immunotherapy. The Company’s two Food and Drug Administration (FDA)-cleared devices use its proprietary Pressure-Enabled Drug Delivery (PEDD) approach to deliver a range of therapeutics: the TriNav Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. PEDD technology is a novel delivery approach designed to address the anatomic limitations of arterial infusion for the pancreas.

arrow icon

What is the price predicton of TLSI Stock?

Wall Street analysts forecast TLSI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TLSI is 11.60 USD with a low forecast of 10.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is TriSalus Life Sciences Inc (TLSI)'s revenue for the last quarter?

TriSalus Life Sciences Inc revenue for the last quarter amounts to 11.57M USD, increased 57.38 % YoY.

arrow icon

What is TriSalus Life Sciences Inc (TLSI)'s earnings per share (EPS) for the last quarter?

TriSalus Life Sciences Inc. EPS for the last quarter amounts to -0.96 USD, increased 700.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for TriSalus Life Sciences Inc (TLSI)'s fundamentals?

The market is revising Downward the revenue expectations for TriSalus Life Sciences, Inc. (TLSI) for FY2025, with the revenue forecasts being adjusted by -0.29% over the past three months. During the same period, the stock price has changed by 34.27%.
arrow icon

How many employees does TriSalus Life Sciences Inc (TLSI). have?

TriSalus Life Sciences Inc (TLSI) has 110 emplpoyees as of December 05 2025.

arrow icon

What is TriSalus Life Sciences Inc (TLSI) market cap?

Today TLSI has the market capitalization of 334.26M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free